New drug combo targets Hard-to-Treat bile duct cancer
NCT ID NCT05994001
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 participants will receive the treatment, and researchers will monitor side effects and how long any benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- candonilimab (a bispecific antibody targeting PD-1 and CTLA-4) and LM-302 (an antibody-drug conjugate targeting Claudin 18.2)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced biliary tract cancer whose disease has progressed after standard therapy.
- What could go wrong
- This is an early-phase trial with only 78 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan hospital, Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Double-Drug attack on Hard-to-Treat cancers
- Liver cancer registry aims to uncover new biomarkers from thousands of patients